Integra LifeSciences (NASDAQ: IART) reported Q1 EPS of $0.39, $0.01 worse than the analyst estimate of $0.40. Revenue for the quarter came in at $258.22 million versus the consensus estimate of $254.22 million.

GUIDANCE:

Integra LifeSciences sees FY2017 EPS of $1.88-$1.94, versus the consensus of $1.91. Integra LifeSciences sees FY2017 revenue of $1.12-1.14 billion, versus the consensus of $1.13 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.